STOCK TITAN

NAVIDEA BIOPHARMS INC - NAVB STOCK NEWS

Welcome to our dedicated page for NAVIDEA BIOPHARMS news (Ticker: NAVB), a resource for investors and traders seeking the latest updates and insights on NAVIDEA BIOPHARMS stock.

NAVIDEA BIOPHARMACEUTICALS, INC. (symbol: NAVB) is a prominent biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates through two main segments: Diagnostic Substances and Therapeutic Development Programs.

At the heart of Navidea's innovation is the Manocept Platform, designed to target the CD206 mannose receptor expressed on activated macrophages. This platform has broad applications across various diagnostic modalities, including Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), imaging, and topical gamma-scanning. Additionally, it facilitates intra-operative and/or optical-fluorescence detection, and the delivery of therapeutic compounds targeting macrophages and diseases involving immune and inflammation responses.

Navidea's product portfolio features NAV4694, a fluorine-18 labeled PET imaging agent used for imaging and evaluating patients exhibiting signs of Alzheimer's disease and mild cognitive impairment. This product underscores the company's commitment to addressing urgent medical needs through advanced diagnostics.

In terms of current projects and partnerships, Navidea continues to build strategic alliances to enhance its product offerings and broaden its market reach. Financially, the company remains focused on strategic investments and operational efficiencies to bolster its position in the biopharmaceutical sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.28%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
none
Rhea-AI Summary
Navidea Biopharmaceuticals provides details on its financial results for Q1 2023 and business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.75%
Tags
-
Rhea-AI Summary
Navidea Biopharmaceuticals, Inc. received a Notice from the NYSE American stating that it is not in compliance with the continued listing standards. The Company has until December 1, 2023, to demonstrate sustained price improvement or effect a reverse stock split. The Notice has no immediate effect on the listing or trading of the Company's common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.79%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.47%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
-
Rhea-AI Summary
Navidea Biopharmaceuticals, Inc. introduces Fix, Fund, Propel approach to drive strategic objectives. The company will issue a press release for Q1 2023 results instead of a conference call and webcast. G2G Ventures is supporting the company's strategic planning and change initiatives. The Fix component focuses on strong leadership, clear priorities, and well-defined roles. Fund aims to secure non-dilutive funding options and partnerships for short, medium, and long-term liquidity. Propel involves creating or improving revenue growth in targeted markets. The company will file Form 10-Q for Q1 2023 and issue a press release with first quarter highlights on May 12th, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.32%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.3%
Tags
none

FAQ

What is the current stock price of NAVIDEA BIOPHARMS (NAVB)?

The current stock price of NAVIDEA BIOPHARMS (NAVB) is $0.001 as of November 20, 2024.

What is the market cap of NAVIDEA BIOPHARMS (NAVB)?

The market cap of NAVIDEA BIOPHARMS (NAVB) is approximately 100.1K.

What is Navidea Biopharmaceuticals, Inc. known for?

Navidea Biopharmaceuticals, Inc. is known for its development and commercialization of precision immunodiagnostic agents and immunotherapeutics.

What is the Manocept Platform?

The Manocept Platform is designed to target the CD206 mannose receptor on activated macrophages, applicable in various diagnostic and therapeutic applications.

What are the main segments of Navidea's operations?

Navidea operates through two segments: Diagnostic Substances and Therapeutic Development Programs.

What is NAV4694?

NAV4694 is a fluorine-18 labeled PET imaging agent used to aid in imaging and evaluating patients with Alzheimer's disease and mild cognitive impairment.

How does Navidea's technology benefit healthcare?

Navidea's technology aids in accurate diagnosis and targeted treatment, particularly in diseases involving immune and inflammation responses.

What diagnostic modalities does the Manocept Platform support?

The Manocept Platform supports SPECT, PET, imaging, topical gamma-scanning, intra-operative, and optical-fluorescence detection.

Does Navidea have any therapeutic products?

Yes, Navidea's platform also includes the delivery of therapeutic compounds targeting macrophages and related diseases.

What diseases does Navidea's technology target?

Navidea's technology targets immune and inflammation-involved diseases.

What is the focus of Navidea's recent projects?

Navidea focuses on strategic partnerships and technological advancements to enhance its diagnostic and therapeutic product offerings.

How does Navidea maintain its financial health?

Navidea remains focused on strategic investments and operational efficiencies to support its financial condition.

NAVIDEA BIOPHARMS INC

NYSE:NAVB

NAVB Rankings

NAVB Stock Data

100.08k
64.16M
35.89%
2.68%
Biotechnology
Healthcare
Link
United States of America
Dublin